OncoMatch/Clinical Trials/NCT06582446
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
Is NCT06582446 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) - Goserelin for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) - Goserelin — A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage HIGH-RISK, VERY HIGH-RISK (NCCNv1.2023)
Excluded: Stage CN+, CM+
High- or very high-risk according to NCCNv1.2023 criteria; Evidence of pelvic nodal disease (cN+) in mpMRI and/or PSMA-PET/CT [excluded]; Evidence of distant metastatic disease (cM+) in mpMRI and/or PSMA-PET/CT [excluded]; Evidence of cT4 disease in mpMRI and/or PSMA-PET/CT [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy to the prostate or pelvis
Cannot have received: radical prostatectomy
Prior radical prostatectomy
Cannot have received: focal therapy
Prior focal therapy approaches to the prostate
Cannot have received: prostate surgery (TURP, HOLEP)
Exception: significant tissue cavity or within the last 6 months prior to randomization
Prostate surgery (TURP or HOLEP) with a significant tissue cavity or prostate surgery (TURP or HOLEP) within the last 6 months prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify